Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

Summary

It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until disease progression or intolerable toxicity or patients withdrawal of consent,and the target sample size is 60 individuals.

Timeline

Start

2020-06-24

Primary completion

2024-12

Completion

2025-05

Drugs

Indications